These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 35337933)
1. Nanoantibiotics to fight multidrug resistant infections by Gram-positive bacteria: hope or reality? Berini F; Orlandi V; Gornati R; Bernardini G; Marinelli F Biotechnol Adv; 2022; 57():107948. PubMed ID: 35337933 [TBL] [Abstract][Full Text] [Related]
2. A therapeutic benefit of daptomycin against glycopeptide-resistant gram-positive cocci bloodstream infections under neutropenia. Matsuda K; Koya J; Toyama K; Ikeda M; Arai S; Nakamura F; Okugawa S; Moriya K; Kurokawa M J Infect Chemother; 2017 Nov; 23(11):788-790. PubMed ID: 28743428 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
4. [Daptomycin in the context of antimicrobial resistance in Gram-positive bacteria]. Candel González FJ Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():10-6. PubMed ID: 22541970 [TBL] [Abstract][Full Text] [Related]
6. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient]. Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. Rybak MJ Clin Microbiol Infect; 2006 Mar; 12 Suppl 1():24-32. PubMed ID: 16445721 [TBL] [Abstract][Full Text] [Related]
12. Novel agents for resistant Gram-positive infections--a review. Strahilevitz J; Rubinstein E Int J Infect Dis; 2002 Mar; 6 Suppl 1():S38-46. PubMed ID: 12044288 [TBL] [Abstract][Full Text] [Related]
13. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. Guskey MT; Tsuji BT Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476 [TBL] [Abstract][Full Text] [Related]
14. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341 [TBL] [Abstract][Full Text] [Related]
15. [Bactericidal effect of daptomycin (LY 146032) compared with vancomycine and teicoplanin against gram-positive bacteria]. Caillon J; Juvin ME; Pirault JL; Drugeon HB Pathol Biol (Paris); 1989 Jun; 37(5 Pt 2):540-8. PubMed ID: 2552378 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Tsai IL; Sun HY; Chen GY; Lin SW; Kuo CH Talanta; 2013 Nov; 116():593-603. PubMed ID: 24148450 [TBL] [Abstract][Full Text] [Related]